Amanta Healthcare shares list at 7% premium over IPO price

[hfe_template id='11223'] [ad_1]
Shares of Amanta Healthcare, a manufacturer of sterile liquid pharmaceuticals and medical devices, listed at a premium of 7% on the exchanges on Tuesday. The stock debuted at Rs 135 on the NSE and Rs 134 on the BSE (6.3% premium) against the issue price of Rs 126.

The Rs 126 crore IPO was entirely a fresh issue of one crore equity shares.


The fresh capital will primarily fund expansion. Approximately Rs 70 crore is earmarked for a new SteriPort manufacturing line at Hariyala, Gujarat, while Rs 30 crore will be allocated to set up another line for small-volume parenterals (SVPs). The remainder will go toward general corporate purposes.

The IPO was open for subscription between September 1 and September 3, with allotment finalized on September 4. Beeline Capital Advisors served as the book-running lead manager, while MUFG Intime India handled registrar responsibilities.


The offering received strong demand, with retail, non-institutional, and institutional categories all oversubscribed, indicating healthy interest despite sector competition. Anchor investors had already committed Rs 37.8 crore ahead of the launch, helping build momentum.

Company profile

Ahmedabad-based Amanta Healthcare, incorporated in 1994, specializes in sterile liquid formulations such as IV fluids, ophthalmic solutions, diluents, and respiratory care products. The company also produces irrigation solutions, first-aid products, and eye lubricants under its medical device portfolio.It markets more than 45 generic products in India through a network of roughly 320 stockists and has a growing export footprint, with registrations in 19 countries and branded product sales in 21 overseas markets, including Africa, Latin America, and the UK.Amanta employs over 1,700 people and uses advanced technologies such as Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) at its facilities.

Financial performance

The company posted revenue of Rs 276.1 crore in FY25, down 2% from Rs 281.6 crore a year earlier, while profit after tax surged to Rs 10.5 crore from Rs 3.6 crore in FY24. EBITDA improved to Rs 61 crore, translating into a margin of 22.1%.

Despite the improved bottom line, analysts have flagged the IPO as “fully priced.” At the upper price band, the stock values the company at a price-to-earnings ratio of nearly 47x on FY25 earnings, leaving limited room for error.

The IPO reflects investor appetite for niche healthcare plays, though long-term returns will depend on the company’s ability to scale exports, control costs, and sustain margins in a competitive industry.

(Disclaimer: Recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times)

Add ET Logo as a Reliable and Trusted News Source
[ad_2] Source link https://mrgaga.in/amanta-healthcare-shares-list-at-7-premium-over-ipo-price/?feed_id=50986&_unique_id=68bfb1b00c708

Comments

Post a Comment

Popular posts from this blog

India VIX jumps 100% in one month. Could fear levels take Nifty further down?

Image
[hfe_template id='11223'] [ad_1] Volatility in Indian equity markets has surged sharply over the past month, with the India VIX nearly doubling as geopolitical tensions and global uncertainty triggered aggressive selling in equities. India VIX, often referred to as the market’s fear gauge, has jumped close to 100% over the past month, reflecting growing nervousness among investors. The spike has coincided with a sharp correction in the broader market, with the Nifty 50 declining about 8% during the same period. The escalation of tensions involving the United States, Israel and Iran has intensified market anxiety in recent days, pushing crude oil prices sharply higher and triggering a global risk-off sentiment. However, analysts note that volatility had already been building even before the conflict escalated, reflecting broader concerns around global growth, foreign capital outflows and stretched valuations in equities. The heightened uncertainty translated into a sharp ...
Read more

Can Sensex, Nifty snap 2-day fall on Monday? 7 factors that could decide market mood this week

Image
[hfe_template id='11223'] [ad_1] Benchmark indices Sensex and Nifty ended the week on a bearish note, closing over a percent lower each as a deepening selloff in IT stocks rattled investor sentiment amid mounting fears of AI-led disruption. Further, stronger-than-expected jobs data for January dampened hopes of a US Fed interest rate cut. Here are 7 factors that could decide market action in the coming week: 1.) Infosys, Wipro ADRs rebound - After a brutal two-day selloff that saw Infosys and Wipro ADRs plunge as much as 14.5%, Friday’s session brought a much-needed breather. Bargain hunting kicked in at lower levels, sparking a sharp rebound as Infosys climbed 3% while Wipro gained 4%—helping both stocks close the week on a far stronger note. International brokerage firm JP Morgan has a message for panic-stricken investors: IT services firms are the indispensable "plumbers of the tech world" and their dividend yields have now hit levels last seen only during ...
Read more

Waaree Energies shares in focus after Q4 profit rises 34% to Rs 619 crore, revenue up 36%

Image
[hfe_template id='11223'] [ad_1] Waaree Energies shares will be in focus on Wednesday after the solar panel maker reported a strong Q4 performance, with net profit rising 34.1% year-on-year (YoY) to Rs 618.9 crore for the quarter ended March 31, 2025. In the same quarter last year, the company had reported a profit of Rs 461.5 crore. Revenue from operations jumped 36.4% to Rs 4,003.9 crore, up from Rs 2,935.8 crore in the year-ago period, according to the company’s regulatory filing. EBITDA more than doubled to Rs 922.6 crore in Q4 FY25, up 120.6% from Rs 418.3 crore in the same quarter last year. The EBITDA margin improved to 23% from 14.3% a year ago. The company produced 2.06 GW of solar modules in the fourth quarter, up from 1.35 GW in the same period last year. For the full year, module production reached 7.13 GW, compared to 4.77 GW in FY24. For the full financial year FY25, revenue rose 27.62% YoY to Rs 14,846.06 crore. Profit after tax more than doubled to Rs 1,9...
Read more